BRIEF published on 10/29/2026 at 17:52, 8 days 11 hours ago IntegraGen: 2026 Half-Year Results Marked by Losses and Legal Proceedings Financial Results Treasury Court Of Appeal Judicial Reorganization IntegraGen
BRIEF published on 10/26/2026 at 17:03, 11 days 12 hours ago IntegraGen Maintains Its Operations Pending the Court of Appeal's Decision Shareholders Court Of Appeal Judicial Reorganization Genomics IntegraGen
BRIEF published on 10/05/2026 at 19:22, 1 month 1 day ago IntegraGen: Decision expected on the divestment plan Judicial Reorganization IntegraGen Commercial Court Takeover Bids Decision Expected
BRIEF published on 09/11/2026 at 20:45, 1 month 25 days ago IntegraGen: two takeover bids filed in receivership Judicial Reorganization Genomics IntegraGen Resumption Commercial Court Of Évry
BRIEF published on 06/15/2026 at 20:31, 4 months 21 days ago IntegraGen is heading towards receivership to ensure its survival. Sustainability Judicial Reorganization Genomics Industrial Partnerships Strategic Activities
BRIEF published on 02/20/2026 at 20:20, 8 months 14 days ago IntegraGen: Annual Review and Continued Strategic Refocusing Revenue Treasury Certifications Profitability Biopharma
BRIEF published on 10/29/2025 at 17:50, 1 year ago IntegraGen: Lower Results, Reduced Expenses in the First Half of 2025 Financial Results Treasury Cost Reduction Genomics CLIA/CAP Certification
BRIEF published on 07/02/2025 at 07:35, 1 year 4 months ago IntegraGen Reports Decline in Sales and Cash Reserves Sales Decline Operational Costs IntegraGen Financing Needs Genomic Analyses
PRESS RELEASE published on 07/02/2025 at 07:30, 1 year 4 months ago Inside Information / Other news releases IntegraGen reports sales of €2.5 million in the first half of 2025, a 31% decrease in sequencing activities at Évry and challenges with cash position leading to exploration of strategic options Sales Cash Position Strategic Options IntegraGen Decrease
BRIEF published on 01/15/2025 at 18:49, 1 year 9 months ago IntegraGen revenue down for 2024 Treasury Growth Turnover Genomics SeqOIA
Published on 11/06/2026 at 22:15, 7 hours 14 minutes ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 16 hours 29 minutes ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 16 hours 59 minutes ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 16 hours 59 minutes ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 20:15, 9 hours 14 minutes ago African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 19:15, 10 hours 14 minutes ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA suspends the interest payment on the bond 2024/2029 due on 8 November 2026.
Published on 11/06/2026 at 19:00, 10 hours 29 minutes ago Finexity AG: FINEXITY issues 2026/2030 bond with a minimum of 7.00% p.a. – either conventionally in a securities account or as a crypto security in a wallet
Published on 11/06/2026 at 18:32, 10 hours 57 minutes ago EQS-Adhoc: Finexity AG: FINEXITY issues 2026/2030 bond
Published on 11/06/2026 at 18:00, 11 hours 29 minutes ago ARVERNE GROUP: Number shares and voting rights
Published on 11/06/2026 at 18:00, 11 hours 29 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 11/06/2026 at 17:54, 11 hours 35 minutes ago Disclosure of Share Capital and Voting Rights as of October 31, 2026
Published on 11/06/2026 at 17:35, 11 hours 54 minutes ago Disclosure of the number of shares and the total number of voting rights as of October 31, 2026
